Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice
Authors
Sebastian, MBarlesi, F
Califano, Raffaele
Mansfield, AS
Blackhall, FH
Flahavan, EM
Davies, J
Arnold, P
Morris, S
Reck, M
Affiliation
Universitatsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am MainIssue Date
2019
Metadata
Show full item recordAbstract
Background For pts with ES-SCLC, guidelines recommend carbo or cis + etop as first-line (1L) tx. However, real-world data (RWD) on tx patterns and outcomes are limited. Here, we describe pt characteristics, tx duration and clinical outcomes associated with these 2 regimens. Methods Pts with ES-SCLC diagnosis (or limited-stage [LS] SCLC who initiated second-line [2L] tx) between 1 Jan 2013 and 31 Aug 2017 (follow-up to 31 Aug 2018) were identified from the US-based Flatiron Health electronic health record–derived database. Pts receiving tx with either carbo + etop or cis + etop were included in the analysis. Results RWD on 2161 pts from 156 tx centres were included; 84% of pts received carbo + etop. See table below for pt characteristics. The median tx duration was 3.4?mo (95% CI: 3.4, 3.4) with carbo + etop and 3.0?mo (95% CI: 2.8, 3.4) with cis + etop. The distribution of tx cycles administered was similar between carbo and cis, with 20% and 28% of pts completing 4 or 6 cycles, respectively. Median overall survival (OS) was 8.3?mo (95% CI: 8.1, 8.7) with carbo + etop and 9.7?mo (95% CI: 9.3, 11.0) with cis + etop. The 1-yr OS rates were 30% (95% CI: 28, 33) and 41% (95% CI: 36, 47), respectively. In pts with Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 and ? 2, median OS was 9.3?mo (95% CI: 8.6, 9.9) and 7.1?mo (95% CI: 6.3, 8.3), respectively. Pts with unknown ECOG PS had a median OS of 8.4?mo (95% CI: 8.0, 8.9). Conclusions Tx duration was similar between the 2 regimens. Pts who received cis + etop had numerically increased OS vs pts who received carbo + etop, as did pts with ECOG PS 0-1. However, these findings may be due to pts receiving cis + etop being fitter (younger and lower ECOG PS) at baseline.Citation
Sebastian M, Barlesi F, Califano R, Mansfield AS, Blackhall FH, Flahavan EM, et al. 66PTreatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice. Ann Oncol. 2019;30(Supplement_2).Journal
Annals of OncologyDOI
10.1093/annonc/mdz071.006Additional Links
https://dx.doi.org/10.1093/annonc/mdz071.006Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz071.006